Novo Nordisk’s oral semaglutide 25 mg achieved up to 16.6% weight loss in a landmark study, rivaling injectable Wegovy. The pill also improved cardiovascular risk factors and physical activity levels.

Investors wiped $70 billion off Novo Nordisk’s market value on Tuesday after the maker of weight-loss drug Wegovy issued a profit warning and named a new CEO, as it battles rising competition in the ...

Danish pharmaceutical giant Novo Nordisk on Tuesday named its new CEO while simultaneously slashing its full-year guidance, citing weaker growth expectations for its blockbuster Wegovy obesity drug in ...

Novo Nordisk NVO is a dominant player in the cardiometabolic space, marketing its blockbuster semaglutide-based (GLP-1) drugs — Ozempic (for type II diabetes [T2D]) and Wegovy (for obesity). These ...

On Friday, August 15, the FDA approved Wegovy (semaglutide) as the first-ever GLP-1 therapy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) — a pivotal moment in the fight ...

LOS ANGELES, June 25 (Reuters) - Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to an analysis of U.S.

Novo Nordisk NVO is a dominant player in the cardiometabolic space, mainly due to the encouraging uptake of its blockbuster semaglutide-based (GLP-1) drugs — Ozempic (for type II diabetes [T2D]) and ...

Danish pharmaceutical major Novo Nordisk has joined hands with Indian drugmaker Emcure Pharmaceuticals to expand the availability of its injectable obesity drug, semaglutide, across India. The ...

LOS ANGELES (Reuters) -Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to an analysis of U.S. pharmacy claims ...